Chemical denervation for the treatment of hypertonia and related motor disorders: Phenol and botulinum toxin

被引:5
|
作者
Glenn, MB
Elovic, E
机构
[1] BOSTON MED CTR,DIV REHABIL MED,BOSTON,MA
[2] JFK JOHNSON REHABIL INST,CTR HEAD INJURIES,EDISON,NJ
[3] UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHYS MED & REHABIL,EDISON,NJ
关键词
botulinum toxin; chemical denervation; chemical neurolysis; neuromuscular blockade; phenol; PAINFUL HEMIPLEGIC SHOULDER; UPPER EXTREMITY SPASTICITY; SPASMODIC TORTICOLLIS; CERVICAL DYSTONIA; NERVE BLOCK; A TOXIN; MUSCLE; INJECTIONS; COMPLICATIONS; RIGIDITY;
D O I
10.1097/00001199-199712000-00005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Chemical neurolysis with phenol and neuromuscular blockade with botulinum toxin (Btx) are two commonly used approaches to chemical denervation (CD) for the treatment of hypertonia and related motor disorders. Physiologic and therapeutic effects, technique, safety and toxicology, and side effects and complications are discussed for each. The patient can be approached by first considering whether CD is indicated in the context of other available options. A kinesiologic and functional evaluation is used to determine the target goals according to impairment and disability. If CD is indicated, the clinician must decide whether neuromuscular blockade with Btx or chemical neurolysis with phenol is a better choice by considering the advantages and disadvantages of each for a given situation. If chemical neurolysis with phenol is indicated, then one must consider whether motor branch or mixed sensorimotor block is more worthwhile.
引用
收藏
页码:40 / 62
页数:23
相关论文
共 50 条
  • [1] Botulinum Toxin Treatment of Motor Disorders in Parkinson Disease-A Systematic Review
    Jabbari, Bahman
    Comtesse, Samira Marie
    TOXINS, 2023, 15 (02)
  • [2] Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population
    Kolaski, Kat
    Ajizian, Samuel J.
    Passmore, Leah
    Pasutharnchat, Nath
    Koman, L. Andrew
    Smith, Beth P.
    AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2008, 87 (07) : 556 - 566
  • [3] Botulinum Toxin Treatment of Movement Disorders
    Safarpour, Yasaman
    Jabbari, Bahman
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (02)
  • [4] Botulinum Toxin Treatment of Movement Disorders
    Yasaman Safarpour
    Bahman Jabbari
    Current Treatment Options in Neurology, 2018, 20
  • [5] Botulinum Toxin for the Treatment of Movement Disorders
    Mary Ann Thenganatt
    Stanley Fahn
    Current Neurology and Neuroscience Reports, 2012, 12 : 399 - 409
  • [6] Botulinum Toxin for the Treatment of Movement Disorders
    Thenganatt, Mary Ann
    Fahn, Stanley
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (04) : 399 - 409
  • [7] Botulinum toxin treatment of secretory disorders
    Naumann, M
    Jost, W
    MOVEMENT DISORDERS, 2004, 19 : S137 - S141
  • [8] Botulinum Toxin Treatment for Cancer-Related Disorders: A Systematic Review
    Safarpour, Delaram
    Jabbari, Bahman
    TOXINS, 2023, 15 (12)
  • [9] The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders
    Gomez-Caravaca, Maria T.
    Caceres-Redondo, Maria T.
    Huertas-Fernandez, Ismael
    Vargas-Gonzalez, Laura
    Carrillo, Fatima
    Carballo, Manuel
    Mir, Pablo
    NEUROLOGICAL SCIENCES, 2015, 36 (02) : 275 - 279
  • [10] Treatment of temporomandibular disorders with botulinum toxin
    Schwartz, M
    Freund, B
    CLINICAL JOURNAL OF PAIN, 2002, 18 (06) : S198 - S203